BioSpace News Archive

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2022.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus ibrutinib targeting ROR1 for patients with Mantle Cell Lymphoma) clinical trial will be highlighted in a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress.

Amarin Corporation plc announces that the UK’s National Institute for Health and Care Excellence is recommending icosapent ethyl for reimbursement and use across the National Health Service in England and Wales to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides, LDL-C levels >1.04 mmol/L and established cardiovascular disease, at a price of £144.21 per 120 soft capsules.

Keymed Biosciences announced that the first patient has been dosed in the Phase I trial of CM350.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at the EHA2022 Hybrid Congress.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data in its signal-seeking clinical study of CY6463.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).

Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura ® in Patients with Geographic Atrophy.

Mednow Inc. (“ Mednow '' or the “ Company ”) (TSXV:MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy, is pleased to announce it will be presenting at Gravitas Securities Inc.’s (“Gravitas”) 3rd Los Angeles Summit, which will be taking place at the Beverly Hills Hotel from June 21st to June 24th, 2022, in Beverly Hills, California.

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company on June 9, 2022 that Nasdaq has determined the Company has regained compliance with the requirements to remain listed in The Nasdaq Capital Market.